Abstract
Background Cognition may be influenced by health-related factors such as blood pressure (BP). However, variations in BP may differentially affect cognition as a function of race. This study investigates the relationship between normal, high, and variable BP and cognitive decline in older Black and White adults.
Methods 2284 participants (1139 Blacks, 1145 Whites, MAge=73.4, SD=6.6) from 3 harmonized cohorts of older adults from the Rush Alzheimer’s Disease Center, were divided into 3 groups (normal, high, variable) based on systolic BP mean and standard deviation. Cognitive scores were computed from multiple assessments in 5 domains (i.e., episodic memory, semantic memory, working memory, processing speed, visuospatial ability). Performance across 19 tests were averaged to create a measure of global cognition. Linear mixed-effects models examined racial differences between BP and cognitive change over an average of 6.7 years.
Results White adults with high or variable BP had faster rates of decline in global cognition compared to Black adults. White adults with high BP declined faster in perceptual speed, semantic memory, and working memory compared to Black adults with high BP, whereas White adults with variable BP had faster rates of decline in all cognitive domains compared to Black adults with variable BP. No racial differences were observed in individuals with normal BP.
Conclusions White older adults with elevated or fluctuating BP show faster rates of cognitive decline compared to older Black adults. Findings highlight the complex interplay between BP and cognitive health, emphasizing the need for targeted interventions to address racial disparities in cognitive well-being.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
N/A
Funding Statement
The RADC/ RUSH cohort studies are supported by the National Institutes of Health, National Institute on Aging (R01 AG17917, R01 AG22018, P30 AG10161, and P30 AG72975).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Written informed consent was obtained from all participants, and research was approved by an Institutional Review Board of Rush University Medical Center. Secondary analyses included in this paper were approved by the Belmont University Institutional Review Board.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced are available online at the RADC Research Resource Sharing Hub. To obtain data from MARS, AA Core, and MAP for research use, please visit the RADC Research Resource Sharing Hub (www.radc.rush.edu).
